Ionis Pharmaceuticals (NasdaqGS:IONS) FY Conference January 13, 2026 11:15 AM ET Company ParticipantsBrett Monia - CEOConference Call ParticipantsJessica Fye - AnalystJessica Fye Great. Good morning, everyone. Welcome. My name's Jessica Fye, Large Cap Biotech Analyst at J.P. Morgan, and we're continuing the 44th Annual Healthcare Conference this morning with Ionis. You're going to hear a presentation from the management team, and then we're going to go into some Q&A. So if you have any questions in the room ...

thCAMBRIDGE, Mass., Dec. 29, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it will participate in and sponsor the 10 Annual MASH-TAG 2026 Conference. Members of MetaVia's business development and clinical teams will attend the conference, which will take place January 8-10 at the Chateaux Deer Valley in Park City, Utah. About MetaViaMetaVia Inc. is a clinical-stage biotechnology company focused ...

Core Insights - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing two key drug candidates: DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [4] Company Overview - MetaVia is developing DA-1726, a novel oxyntomodulin (OXM) analogue that acts as a dual agonist for glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), showing potential for superior weight loss and glucose control compared to selective GLP1R agonists [4] - DA-1726 demonstrated best-in-class potential in a Phase 1 multiple ascending dose trial, indicating effectiveness in weight loss, glucose control, and waist reduction [4] - DA-1241 is a G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of gut peptides GLP-1, GIP, and PYY, showing positive effects on liver inflammation, lipid metabolism, and glucose metabolism in pre-clinical studies [4] - In a Phase 2a clinical study, DA-1241 exhibited direct hepatic action alongside glucose-lowering effects [4] Upcoming Events - MetaVia will participate in several upcoming conferences, including: - Wells Fargo Healthcare Conference from September 3-5, where CEO Hyung Heon Kim will attend [7] - H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, featuring a fireside chat and an on-demand presentation available from September 5 [7] - Obesity Science & Innovation 2025 Congress on September 16-17, where Mr. Kim will present an overview focusing on DA-1726 [7] - Fierce Biotech Week from October 7-9, with Mr. Kim's attendance [7]

Core Insights - MetaVia Inc. reported promising results from its Phase 1 clinical trial of DA-1726, indicating a dose-dependent response in body weight reduction, with significant differences in BMI and body weight compared to placebo [1][2][4] - DA-1726 demonstrated a maximum weight loss of -6.3% and a mean weight loss of -4.3% at the 32 mg dose, alongside notable reductions in fasting glucose and waist circumference [3][4] - The drug showed a favorable safety profile, with no significant cardiovascular effects observed, and a slight decrease in heart rate across most treatment groups [4][7] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, particularly obesity [10] - The company is advancing DA-1726, a dual agonist targeting GLP-1 and glucagon receptors, which aims to improve weight loss outcomes compared to existing therapies [9][10] Clinical Trial Details - The Phase 1 trial was a randomized, double-blind, placebo-controlled study involving 36 subjects, assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of DA-1726 [6] - The trial's primary endpoint was to evaluate the safety and tolerability of DA-1726, while secondary endpoints included pharmacokinetic assessments and exploratory metabolic parameters [6] Future Directions - MetaVia plans to conduct a Phase 1 Part 3 study to evaluate DA-1726 in patients who discontinued other GLP-1 agonists, aiming to demonstrate improved tolerability and weight loss outcomes [5] - Additional cohorts will be added to determine the maximum tolerated dose of DA-1726, with expectations of enhanced efficacy at higher doses [5]